PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 203 filers reported holding PDL BIOPHARMA INC in Q2 2015. The put-call ratio across all filers is 0.19 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $1,432,000 | -37.6% | 675,286 | -1.4% | 0.00% | -33.3% |
Q3 2016 | $2,295,000 | +6.2% | 685,096 | -0.4% | 0.00% | 0.0% |
Q2 2016 | $2,160,000 | +5.4% | 687,978 | +11.8% | 0.00% | 0.0% |
Q1 2016 | $2,050,000 | -5.8% | 615,620 | +0.1% | 0.00% | 0.0% |
Q4 2015 | $2,177,000 | -29.4% | 614,958 | +0.3% | 0.00% | -25.0% |
Q3 2015 | $3,085,000 | -21.3% | 613,242 | +0.6% | 0.00% | -20.0% |
Q2 2015 | $3,919,000 | +24.6% | 609,426 | +36.3% | 0.01% | +25.0% |
Q1 2015 | $3,146,000 | -7.3% | 447,124 | +1.6% | 0.00% | 0.0% |
Q4 2014 | $3,394,000 | +2.7% | 440,177 | -0.5% | 0.00% | -20.0% |
Q3 2014 | $3,305,000 | -22.3% | 442,480 | +0.7% | 0.01% | -16.7% |
Q2 2014 | $4,251,000 | +15.2% | 439,201 | -1.1% | 0.01% | +20.0% |
Q1 2014 | $3,690,000 | +12.7% | 443,990 | +14.4% | 0.01% | 0.0% |
Q4 2013 | $3,275,000 | +3.1% | 387,990 | -2.7% | 0.01% | 0.0% |
Q3 2013 | $3,177,000 | +10.6% | 398,593 | +7.1% | 0.01% | 0.0% |
Q2 2013 | $2,873,000 | – | 372,104 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HAYS ADVISORY LLC | 1,037,600 | $6,672,000 | 0.97% |
Global X Management CO LLC | 2,435,411 | $15,660,000 | 0.86% |
Advisors Asset Management, Inc. | 5,373,113 | $34,549,000 | 0.47% |
Gotham Asset Management, LLC | 7,233,838 | $46,514,000 | 0.39% |
TFS CAPITAL LLC | 582,438 | $3,745,000 | 0.37% |
LOMBARDIA CAPITAL PARTNERS LLC | 1,637,611 | $10,530,000 | 0.36% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 95,122 | $611,634,000 | 0.33% |
FIRST TRUST ADVISORS LP | 17,536,793 | $112,762,000 | 0.29% |
Arrow Investment Advisors, LLC | 214,595 | $1,380,000 | 0.28% |
GSA CAPITAL PARTNERS LLP | 954,853 | $6,140,000 | 0.24% |